The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
|
|
- Anastasia Agnes Pope
- 5 years ago
- Views:
Transcription
1 The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall potential risks or benefits of a product which are based on an evaluation of an entire research program. Before prescribing any Takeda products, healthcare professionals should consult prescribing information for the product approved in their country.
2 SYNOPSIS Name of Sponsor: Takeda Europe Research & Development Centre Ltd. Name of Active Ingredient: Lapaquistat acetate Name of Finished Product: Not applicable Investigators/Study Centers: 73 sites in the Russian Federation, Lithuania, Latvia, Germany, the United Kingdom, Estonia, Serbia and Montenegro, Finland, Poland, and Hungary. Publication: None Study Period: 26 October 2005 to 09 January 2007 Phase of Development: Phase 3 OBJECTIVES Primary: The primary objective of this study was to evaluate the reduction in low-density lipoprotein cholesterol (LDL-C) in subjects with primary dyslipidemia when treated with lapaquistat acetate 100 mg once daily (QD) vs ezetimibe 10 mg QD for 24 weeks. Secondary: The secondary objectives of this study were: To evaluate the reduction in LDL-C in subjects with primary dyslipidemia when treated with ezetimibe 10 mg vs lapaquistat acetate 100 mg administered in combination with ezetimibe 10 mg for 24 weeks. To evaluate safety and tolerability (adverse events, safety laboratory tests, physical examination, vital signs, best corrected visual acuity [BCVA], and electrocardiogram [ECG]) and changes in lipid variables: total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), very-low-density lipoprotein cholesterol (VLDL-C), apolipoprotein A1 (Apo A1), apolipoprotein B (Apo B), and non HDL-C. The percentages of subjects achieving LDL-C levels of <3.37 mmol/l (130 mg/dl) and <2.59 mmol/l (100 mg/dl) were also evaluated. The effects of lapaquistat acetate 100 mg QD and lapaquistat acetate 100 mg QD administered in combination with ezetimibe 10 mg QD vs ezetimibe 10 mg QD for 24 weeks on other lipid variables were also evaluated.
3 METHODOLOGY This was a double-blind, randomized, double-dummy, parallel group, multicenter, phase 3 study to evaluate the reduction in LDL-C in subjects with primary dyslipidemia when treated with lapaquistat acetate 100 mg QD or lapaquistat acetate 100 mg administered in combination with ezetimibe 10 mg QD vs ezetimibe 10 mg QD for 24 weeks. The study consisted of a Screening Visit, a 6-week Dietary Run-In Period, and a 24-week Treatment Period. Subjects who initially met study eligibility criteria entered a 6-week diet stabilization period (on a standardized diet such as the therapeutic lifestyle change diet) and returned to the site at Weeks -2 and -1 (and at an optional visit 1 week later if necessary) for repeat qualifying lipid tests. Qualifying subjects were randomized to treatment after stratification by their Baseline TG level ( mmol/l or >1.695 mmol/l [ 150 mg/dl or >150 mg/dl]). Subjects self-administered study drug (lapaquistat acetate 100 mg QD, ezetimibe 10 mg QD, or coadministration of lapaquistat acetate 100 mg with ezetimibe 10 mg QD) from Day 1 through Week 24, and returned to the site at Weeks 2, 4, 8, 12, 16, 20, and 24 for study procedures. Number of Subjects: Planned: 1035 subjects (460 in each of the lapaquistat acetate 100 mg and ezetimibe 10 mg groups, and 115 in the lapaquistat acetate 100 mg/ezetimibe 10 mg coadministration group). Analyzed: Full analysis set: 1263 subjects (561 lapaquistat acetate 100 mg, 561 ezetimibe 10 mg, 141 lapaquistat acetate 100 mg/ezetimibe 10 mg coadministration). Safety analysis set: 1263 subjects (561 lapaquistat acetate 100 mg, 561 ezetimibe 10 mg, 141 lapaquistat acetate 100 mg/ezetimibe 10 mg coadministration). Diagnosis and Main Criteria for Inclusion: To qualify for study participation, a subject must have been a man or woman, aged at least 18 years, with a documented history of dyslipidemia who met the following lipid criteria prior to randomization: (1) mean fasting LDL-C levels 3.36 mmol/l ( 130 mg/dl) and 5.6 mmol/l ( 220 mg/dl) from 2 consecutive samples taken no less than 1 week apart, with the difference between the 2 values not exceeding 15% of the higher value, and (2) mean TG value 4.52 mmol/l ( 400 mg/dl) from 2 consecutive samples taken no less than 1 week apart, with the upper value for either sample 5.0 mmol/l ( 450 mg/dl). Test Product Dose and Mode of Administration Lot Numbers Lapaquistat acetate Matching placebo 100 mg tablet, oral, QD tablet, oral, QD Z , Z Z , Z Reference Therapy Dose and Mode of Administration Lot Numbers Ezetimibe Matching placebo 10 mg capsule, oral, QD capsule, oral, QD , , Duration of Treatment: The treatment duration was 24 weeks, which followed a 6- to 7-week Run-in Period. Criteria for Evaluation: Efficacy: The primary efficacy variable was fasting plasma direct LDL-C concentration based on direct measurement. The secondary efficacy variables were the fasting plasma concentrations of calculated LDL-C, non HDL-C (derived as TC minus HDL-C), TC, Apo B, TG, HDL-C, Apo A1, VLDL-C, derived ratios (TC/HDL-C, LDL-C/HDL-C, and Apo B/Apo A1), high-sensitivity C-reactive protein (hs-crp), and the proportion of subjects who achieved direct fasting plasma LDL-C concentrations of <3.37 and <2.59 mmol/l (<130 and <100 mg/dl) at the Week 24 (or early withdrawal) Visit.
4 Safety: Safety variables included adverse events, clinical laboratory results (chemistry, hematology, and urinalysis), physical examination findings, ECG assessments, BCVA results, and vital signs. Statistical Methods: All statistical analyses were based on the statistical analysis plan, which was finalized before unblinding. The primary efficacy analysis was based on the percent change from Baseline to Week 24 (or time of early withdrawal) in direct fasting plasma LDL-C value. Treatment groups were compared using an analysis of covariance (ANCOVA) model with treatment as factor and Baseline value as covariate. For the primary treatment comparison, a sequential test of superiority first and noninferiority of lapaquistat acetate 100 mg vs ezetimibe 10 mg was performed. If the upper limit of the 95% confidence interval (CI) for the difference in least square (LS) treatment means (lapaquistat acetate 100 mg minus ezetimibe 10 mg) was less than zero, superiority of lapaquistat acetate 100 mg over ezetimibe 10 mg was claimed. If the upper limit of the 95% CI was less than or equal to the noninferiority margin of 3%, then noninferiority of lapaquistat acetate 100 mg to ezetimibe 10 mg was claimed. Secondary variables were analyzed using the same analysis model as the primary analysis. For time-effect displays, primary and secondary variables were summarized and analyzed by study visit, using ANCOVA models similar to the model used in the primary analysis. For TG, additional analysis was performed using the Wilcoxon rank-sum test; treatment differences in median percent change from Baseline and 95% confidence intervals were calculated based on the Hodges-Lehmann method and a distribution-free confidence interval method. For hs-crp, treatment differences in median change from Baseline and 95% confidence intervals were calculated based on the Hodges- Lehmann method and a distribution-free confidence interval method. Treatment groups were compared with an ANCOVA model using Tukey normalized ranks. The proportions of subjects who achieved LDL-C concentrations of <3.37 and <2.59 mmol/l (<130 and <100 mg/dl) at Week 24 (or time of early withdrawal) were summarized; no formal statistical analysis was performed. Numbers of subjects reaching LDL-C goals at the Final Visit determined with a risk-based algorithm devised by the National Cholesterol Education Program (NCEP) were also analyzed using a logistic regression model with terms for treatment, risk category, and Baseline LDL-C. Additional post hoc analyses of the primary and secondary efficacy variables were conducted within subgroups of subjects with Baseline TG values above and above mmol/l (150 and 200 mg/dl). In the safety analyses, adverse events were coded using the Medical Dictionary for Regulatory Activities (Version 8.1) and summarized using descriptive statistics. Clinical laboratory test results were summarized descriptively by treatment. Markedly abnormal laboratory values were summarized by treatment group, including the number and percentage of subjects in each laboratory parameter group. Shift tables were produced that included the number of subjects per group with low, normal, or high values with respect to the reference ranges, and the number and percentage of subjects in each shift combination. Descriptive statistics of vital signs, ECG intervals, and BCVA evaluations were produced for each treatment group. SUMMARY OF RESULTS Subject Disposition: There were 1267 subjects randomized to treatment: 562 in the lapaquistat acetate 100 mg group, 564 in the ezetimibe 10 mg group, and 141 in the lapaquistat acetate/ezetimibe coadministration group. A total of 1096 subjects completed the study, 167 subjects (14.1% receiving lapaquistat acetate 100 mg, 11.5% receiving ezetimibe 10 mg, and 16.3% receiving lapaquistat acetate/ezetimibe coadministration) prematurely discontinued the study, and 4 subjects failed to receive study drug (1 in the lapaquistat acetate 100 mg group and 3 in the ezetimibe 10 mg group). The most common reasons for discontinuation were adverse events and voluntary withdrawal. All subjects were White, and the study population was predominantly female (63.1%), with a mean age of 55.4 years. There were no important differences between treatment groups in any of the Baseline demographic characteristics or Baseline efficacy parameters.
5 Efficacy Results: Summary of Primary and Secondary Lipid Variables: Change From Baseline at Week 24 (LOCF) % Change From Baseline, LS Mean (SE) LAP 100 mg/ Variable LAP 100 mg (n=561) Ezetimibe 10 mg (n=561) Ezetimibe 10 mg (n=141) Difference Between LAP and Ezetimibe (95% CI) Direct LDL-C (0.626) (0.627) (1.247)* (-5.99, -2.52) Calculated LDL-C (0.638) (0.638) (1.273)* (-5.99, -2.45) Non HDL-C (0.601) (0.600) (1.199)* (-5.78, -2.45) TC (0.481) (0.480) (0.959)* (-5.16, -2.50) Apo B (0.610) (0.610) (1.217)* (-6.49, -3.11) TG (a) * (-8.04, -1.66) P=0.003 HDL-C 1.74 (0.626) 3.79 (0.624) 3.05 (1.247) (-3.79, -0.32) P=0.020 Apo A (0.520) 6.63 (0.520) 7.07 (1.037) (-2.73, 0.16) P=0.082 VLDL-C (1.345) (1.344) (2.681)* (-8.30, -0.84) P=0.016 *P<0.05 vs lapaquistat acetate 100 mg and ezetimibe 10 mg. (a) For TG, changes from Baseline are medians, not means. LAP = lapaquistat acetate. The efficacy results for the primary and main secondary variables are presented in the above table. In addition, in direct LDL-C reductions, the difference between lapaquistat acetate 100 mg and ezetimibe 10 mg was statistically significant at all visits throughout the 24-week Treatment Period. In subgroup analyses of the primary variable, all differences between lapaquistat acetate 100 mg and ezetimibe 10 mg were statistically significant in subgroups based on age, body mass index, Baseline TG value, and among female subjects. All differences between lapaquistat acetate/ezetimibe coadministration and either monotherapy were highly statistically significant. Of subjects with a Baseline direct LDL-C value 3.37 mmol/l, 59.7% of lapaquistat acetate 100 mg subjects achieved levels below 3.37 mmol/l by the Week 24 (or early withdrawal) Visit, compared with 46.1% of ezetimibe 10 mg subjects. Of this same subgroup, 16.7% of lapaquistat acetate 100 mg subjects and 5.8% of ezetimibe 10 mg subjects achieved levels below 2.59 mmol/l by the Week 24 (or early withdrawal) Visit. Corresponding proportions of subjects in the lapaquistat acetate/ezetimibe coadministration group were 86.3% and 60.4%, respectively. Of subjects above their target LDL-C level at Baseline based on risk-modified NCEP criteria, 67.3% of those receiving lapaquistat acetate 100 mg, 58.8% receiving ezetimibe 10 mg, and 88.9% receiving lapaquistat acetate/ezetimibe coadministration were below the goal at the Final Visit. In this analysis, the difference between lapaquistat acetate 100 mg and ezetimibe 10 mg was statistically significant. In the lipid ratios LDL-C/HDL-C, TC/HDL-C, and Apo B/Apo A1, reductions seen with lapaquistat acetate 100 mg were statistically significantly larger than those with ezetimibe 10 mg at all time points. The largest reductions were seen with lapaquistat acetate/ezetimibe coadministration. Median hs-crp changes at Week 24 were % for lapaquistat acetate 100 mg, 0.00% for ezetimibe 10 mg, and % for lapaquistat acetate/ezetimibe
6 coadministration. The differences between lapaquistat acetate and ezetimibe monotherapy were statistically significant at all post-baseline visits. Results of post hoc analyses of primary and secondary efficacy variables in subgroups of subjects with Baseline TG values above and above mmol/l were similar to those of the main analyses. Safety Results: Of the 1267 subjects enrolled in this study, 1263 were exposed to study drug. A total of 438 subjects (34.7%) experienced an adverse event during the study (36.5% of lapaquistat acetate subjects, 32.8% of ezetimibe subjects, and 34.8% of lapaquistat acetate/ezetimibe coadministration subjects). Adverse events considered possibly, probably, or definitely related to study drug occurred in 214 subjects (16.9%): 19.4% of lapaquistat acetate 100 mg subjects, 13.2% of ezetimibe 10 mg subjects, and 22.0% of lapaquistat acetate/ezetimibe coadministration subjects. Twenty-four subjects (1.9%) experienced a severe event (2.1%, 1.6%, and 2.1% of subjects in the lapaquistat acetate 100 mg, ezetimibe 10 mg, and lapaquistat acetate/ezetimibe coadministration groups, respectively). Adverse events that occurred in at least 3% of subjects in any treatment group were nausea, nasopharyngitis, increased ALT, and increased AST. Two subjects died during the study, 1 of glioblastoma multiforme and 1 of colon carcinoma; the events leading to death occurred too soon after the beginning of study medication to suggest a possible effect of lapaquistat acetate. Twenty-five subjects (12 lapaquistat acetate 100 mg, 9 ezetimibe 10 mg, and 4 lapaquistat acetate/ezetimibe coadministration) experienced a total of 31 treatment-emergent serious adverse events, and all but 8 of these events were judged by the investigator to be not related to study drug. There were 93 subjects (54 [9.6%] of lapaquistat acetate 100 mg subjects, 22 [3.9%] of ezetimibe 10 mg subjects, and 17 [12.1%] of lapaquistat acetate/ezetimibe coadministration subjects) who either withdrew from the study (79 subjects) or temporarily discontinued study drug (14 subjects) because of an adverse event. Elevations in liver function values, and adverse events representing such elevations, occurred at higher incidences with lapaquistat acetate 100 mg and lapaquistat acetate/ezetimibe coadministration than with ezetimibe 10 mg. ALT elevations to >3xULN at consecutive visits occurred in 16 (2.9%) subjects receiving lapaquistat acetate 100 mg, 4 (0.7%) subjects receiving ezetimibe 10 mg, and 10 (7.1%) subjects receiving lapaquistat acetate/ezetimibe coadministration. No pattern of time to onset was evident, and none of the elevations was accompanied by increases in bilirubin. Most of the subjects experiencing such elevations withdrew from the study. In all cases where subsequent values were available, the elevations resolved either to the normal range or to 3xULN or below. Five subjects, 2 (0.4%) receiving lapaquistat acetate 100 mg and 3 (2.1%) receiving lapaquistat acetate/ezetimibe coadministration, had ALT elevations above 10xULN at least once during the study. No subject receiving lapaquistat acetate 100 mg experienced a CPK elevation to >10xULN. One subject in the ezetimibe 10 mg group experienced an elevation of CPK to 1783 IU/L on Day 1, before taking the first dose of study medication. No other CPK value >10xULN was seen in this study. Sixteen subjects had CPK elevations that were reported as adverse events: 7 (1.2%) lapaquistat acetate 100 mg subjects, 6 (1.1%) ezetimibe 10 mg subjects, and 3 (2.1%) lapaquistat acetate/ezetimibe coadministration subjects. Two of these elevations, both in the lapaquistat acetate 100 mg group, led to the subject s withdrawal. Thirteen subjects (8 [1.4%] lapaquistat acetate 100 mg, 2 [0.4%] ezetimibe 10 mg, and 3 [2.1%] lapaquistat acetate/ezetimibe coadministration) had muscle-related adverse events that led to withdrawal. There were no major findings in hematology, urinalysis, vital signs, ECGs, physical examination, or BCVA results.
7 CONCLUSIONS: Administration of lapaquistat acetate 100 mg QD for 24 weeks was consistently more effective than ezetimibe 10 mg QD in reducing LDL-C levels in subjects with primary dyslipidemia. Statistically significant differences in favor of lapaquistat acetate were seen in effects on mean direct and calculated LDL-C, non HDL-C, TC, Apo B, and VLDL-C; median hs-crp and TG; and all of the lipid ratios. Throughout the efficacy variables, coadministration of the 2 agents together provided significant additive effects over either monotherapy. In this study, lapaquistat acetate and ezetimibe, and the coadministration of both therapies, were generally safe and well tolerated. However, hepatic enzyme elevations and adverse events representing such elevations occurred at higher incidences in the coadministration group than with either monotherapy. Date of Report: 26 February 2008
2.0 Synopsis. Choline fenofibrate capsules (ABT-335) M Clinical Study Report R&D/06/772. (For National Authority Use Only) Name of Study Drug:
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Choline Fenofibrate (335) Name of Active Ingredient:
More information(For National Authority Use Only) Name of Study Drug: to Part of Dossier:
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: ABT-335 Name of Active Ingredient: Page: ABT-335, A-7770335.115
More informationClinical Trial Synopsis TL-OPI-518, NCT#
Clinical Trial Synopsis, NCT# 00225264 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl vs Glimepiride
More informationMipomersen (ISIS ) Page 2 of 1979 Clinical Study Report ISIS CS3
(ISIS 301012) Page 2 of 1979 2 SYNOPSIS ISIS 301012-CS3 synopsis Page 1 Title of Study: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics,
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More information(For National Authority Use Only) Name of Study Drug: to Part of Dossier:
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Niaspan Name of Active Ingredient: Page: Niacin extended-release
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationClinical Trial Synopsis TL-OPI-525, NCT#
Clinical Trial Synopsis, NCT#00762736 Title of Study: A Phase II, Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study of the Efficacy, Safety, and Tolerability of Pioglitazone HCl (ACTOS
More informationINDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER
2. SYNOPSIS Title of Study: An Open-Label, 2-Cohort Study to Evaluate the 2-Way Interaction Between Multiple Doses of and a Single Dose of Rosuvastatin (Crestor ), to Assess the Dose Proportionality of,
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationSponsor Novartis. Generic Drug Name Vildagliptin/Metformin. Therapeutic Area of Trial Type 2 diabetes. Approved Indication Type 2 diabetes
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin/Metformin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Study Number CLMF237A2309
More informationStudy Code: Date: 27 July 2007
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationSYNOPSIS 2/198 CSR_BDY-EFC5825-EN-E02. Name of company: TABULAR FORMAT (For National Authority Use only)
SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose (rimonabant 20 mg) multicenter study of long-term glycemic control with rimonabant in treatment-naïve
More informationIndividual Study Table Referring to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI424136
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Reyataz Name of Active Ingredient: Individual Study Table Referring to the Dossier (For National Authority Use Only) SYNOPSIS for
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationClinialTrials.gov Identifier: HOE901_4020 Insulin Glargine Date: Study Code: This was a multicenter study that was conducted at 59 US sites
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:
More informationStudy Center(s): The study was conducted at 39 study sites in Japan.
SYNOPSIS Issue Date: 20 NOVEMBER 2012 Name of Sponsor/Company Janssen Pharmaceutical K. K. Name of Finished Product CONCERTA Name of Active Ingredient(s) Methylphenidate HCl Protocol No.: JNS001-JPN-A01
More informationImmediate-release Hydrocodone/Acetaminophen M Abbreviated Clinical Study Report R&D/08/1020
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Hydrocodone Bitartrate- Acetaminophen (NORCO ) Name of
More information2.0 Synopsis. ABT-711 M Clinical Study Report R&D/06/573. (For National Authority Use Only) to Part of Dossier: Volume:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Depakote ER Name of Active Ingredient: Divalproex sodium (ABT-711) Individual Study Table Referring to Part of Dossier: Volume: Page: (For National
More informationPage: 17 December 2012 (Study M13-692) 22 October 2013 (Study M13-692)
2.0 Synopsis AbbVie Inc. Name of Study Drug: Adalimumab Name of Active Ingredient: D2E7 Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Title of Studies:
More informationProtocol GTC : A Randomized, Open Label, Parallel Design Study of Sevelamer Hydrochloride (Renagel ) in Chronic Kidney Disease Patients.
Protocol GTC-68-208: A Randomized, Open Label, Parallel Design Study of Sevelamer Hydrochloride (Renagel ) in Chronic Kidney Disease Patients. These results are supplied for informational purposes only.
More informationProduct: Denosumab (AMG 162) Clinical Study Report: month Primary Analysis Date: 21 November 2016 Page 1
Date: 21 November 2016 Page 1 2. SYNOPSIS Name of Sponsor: Amgen Inc., Thousand Oaks, CA, USA Name of Finished Product: Prolia Name of Active Ingredient: denosumab Title of Study: Randomized, Double-blind,
More informationSynopsis (C0743T09 PHOENIX 2)
Monoclonal antibody () Synopsis ( PHOENIX 2) Protocol: EudraCT No.: 2005-003530-17 Title of the study: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationSYNOPSIS. ER OROS Paliperidone: Clinical Study Report R SCH-301
SYNOPSIS Protocol No.: R076477-SCH-301 Title of Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With an Open-Label Extension Evaluating Extended Release OROS Paliperidone in
More informationClinical Trial Synopsis
Clinical Trial Synopsis Title of Study: A Phase III, Open-Label, Fixed-Dose Study to Determine the Safety of Long-Term Administration of TAK-375 in Subjects With Chronic Insomnia Protocol Number: Name
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. PROPRIETARY DRUG NAME / GENERIC DRUG NAME: Caduet / Amlodipine
More information2.0 Synopsis. ABT-333 M Clinical Study Report R&D/09/956
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: ABT-333 Volume: Name of Active Ingredient: Page: Sodium N-{6-[3-tert-butyl-5-(2,4-
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationIndividual Study Table Referring to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI424138
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Reyataz Name of Active Ingredient: Atazanavir () Individual Study Table Referring to the Dossier (For National Authority Use Only)
More informationSYNOPSIS OF RESEARCH REPORT (PROTOCOL BC20779)
TITLE OF THE STUDY / REPORT No. / DATE OF REPORT INVESTIGATORS / CENTERS AND COUNTRIES Clinical Study Report Protocol BC20779: Multicenter, double-blind, randomized, placebo-controlled, dose ranging phase
More informationSYNOPSIS. Clinical Study Report CN138002: Addendum 1. Individual Study Table Referring to the Dossier
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Abilify Name of Active Ingredient: aripiprazole Individual Study Table Referring to the Dossier (For National Authority Use Only)
More informationIndividual Study Table Referring to Part of the Dossier. Use only) Name of Finished Product:
SYNOPSIS Fresenius Title of the study: A double-blind, randomized study comparing the safety and torelance of SMOFlipid 20% and Intralipid 20% in long-term treatment with parenteral nutrition Coordinating
More information2.0 Synopsis. Paricalcitol Capsules M Clinical Study Report R&D/15/0380. (For National Authority Use Only)
2.0 Synopsis AbbVie Inc. Name of Study Drug: ABT-358/Zemplar (paricalcitol) Capsules Name of Active Ingredient: paricalcitol Individual Study Table Referring to Part of Dossier: Volume: Page: (For National
More informationClinical Trial Synopsis TL-OPI-516, NCT#
Clinical Trial Synopsis, NCT#00225277 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl Versus
More informationStudy No. 178-CL-008 Report Final Version, 14 Dec 2006 Reissued Version, 18 Jul 2011 Astellas Pharma Europe B.V. Page 13 of 122
Page 13 of 122 3 SYNOPSIS Title of study: (International) Study No: A randomized, double-blind, parallel group, proof-of-concept study of in comparison with placebo and tolterodine in patients with symptomatic
More informationINDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER Volume: Page:
SYNOPSIS Protocol No.: CR004357 Title of Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 50 and 100 mg eq. of Paliperidone Palmitate in Subjects With
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. GENERIC DRUG NAME / COMPOUND NUMBER: Tofacitinib / CP-690,550
More informationPitavastatin 4 mg vs. Pravastatin 40 mg in HIV Dyslipidemia: Post- Hoc Analysis of the INTREPID Trial Based on the Independent CHD Risk Factor for Age
Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV Dyslipidemia: Post- Hoc Analysis of the INTREPID Trial Based on the Independent CHD Risk Factor for Age Craig A. Sponseller, Masaya Tanahashi, Hideki Suganami,
More informationIndividual Study Table Referring to Item of the Submission: Volume: Page:
2.0 Synopsis Name of Company: Abbott Laboratories Name of Study Drug: Meridia Name of Active Ingredient: Sibutramine hydrochloride monohydrate Individual Study Table Referring to Item of the Submission:
More informationSponsor. Novartis Pharmaceuticals Corporation Generic Drug Name. Agomelatine Therapeutic Area of Trial. Major depressive disorder Approved Indication
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major depressive disorder Approved Indication Investigational drug Study
More informationClinical Trial Study Synopsis
Clinical Trial Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationSummary ID#7029. Clinical Study Summary: Study F1D-MC-HGKQ
CT Registry ID# 7029 Page 1 Summary ID#7029 Clinical Study Summary: Study F1D-MC-HGKQ Clinical Study Report: Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated with Bipolar
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationSCIENTIFIC STUDY REPORT
PAGE 1 18-NOV-2016 SCIENTIFIC STUDY REPORT Study Title: Real-Life Effectiveness and Care Patterns of Diabetes Management The RECAP-DM Study 1 EXECUTIVE SUMMARY Introduction: Despite the well-established
More informationBRL /RSD-101C0D/1/CPMS-704. Report Synopsis
Report Synopsis Study Title: A Randomized, Multicenter, 10-Week, Double-Blind, Placebo- Controlled, Flexible-Dose Study to Evaluate the Efficacy and Safety of Paroxetine in Children and Adolescents with
More informationProduct: Denosumab (AMG 162) Synopsis Clinical Study Report: Date: 29 July 2008
Name of Sponsor: Amgen Inc., Thousand Oaks, CA Name of Finished Product: Denosumab (AMG 162) Name of Active Ingredient: Fully human monoclonal antibody to receptor activator for nuclear factor-κb ligand
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More information(a) y = 1.0x + 0.0; r = ; N = 60 (b) y = 1.0x + 0.0; r = ; N = Lot 1, Li-heparin whole blood, HbA1c (%)
cobas b system - performance evaluation Study report from a multicenter evaluation of the new cobas b system for the measurement of HbAc and lipid panel Introduction The new cobas b system provides a point-of-care
More informationSYNOPSIS. Study center(s) This study was conducted in the United States (128 centers).
Drug product: Drug substance(s): Document No.: Edition No.: Study code: Date: SYMBICORT pmdi 160/4.5 µg Budesonide/formoterol SD-039-0725 17 February 2005 SYNOPSIS A Twelve-Week, Randomized, Double-blind,
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationNew Evidence reports on presentations given at EULAR Safety and Efficacy of Tocilizumab as Monotherapy and in Combination with Methotrexate
New Evidence reports on presentations given at EULAR 2009 Safety and Efficacy of Tocilizumab as Monotherapy and in Combination with Methotrexate Report on EULAR 2009 presentations Tocilizumab inhibits
More informationAdalimumab M Clinical Study Report Final R&D/14/1263. Page:
Synopsis AbbVie Inc. Name of Study Drug: Adalimumab Name of Active Ingredient: Adalimumab Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Title of Study:
More informationARBITER 6-HALTS HDL And LDL Treatment Strategies
ARBITER 6-HALTS HDL And LDL Treatment Strategies Extended-Release Niacin or Ezetimibe and Carotid Intima Media Thickness Allen J. Taylor, M.D. Todd C. Villines, M.D. Eric J. Stanek, Pharm.D. Patrick J.
More informationSYNOPSIS. Clinical Study Report AI Addendum #1. Open-label Dosing Phase
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Individual Study Table Referring to the Dossier (For National Authority Use Only) Name of Active Ingredient: Entecavir SYNOPSIS Clinical
More informationS^t _j4 A-N.1^.^ A _ WE 2
S^t _j4 A-N.1^.^ A _ WE 2 Name of Sponsor: Amgen Inc. Name of Finished Product: Denosumab (AMG 162) Name of Active Ingredient: Fully human monoclonal antibody to RANKL Title of Study: A Randomized Study
More informationProduct: Cinacalcet hydrochloride Clinical Study Report: Page 2 of 670
Page 2 of 670 2. SYNOPSIS Name of Sponsor: mgen Inc., Thousand Oaks, C Name of Finished Product: Cinacalcet hydrochloride (Sensipar, Mimpara ) Name of ctive Ingredient: cinacalcet (cinacalcet hydrochloride
More informationSynopsis. Adalimumab M Clinical Study Report R&D/09/060. (For National Authority Use Only) to Part of Dossier: Name of Study Drug:
Synopsis Abbott Laboratories Name of Study Drug: Individual Study Table Referring to Part of Dossier: Volume: (For National Authority Use Only) Name of Active Ingredient: Page: Title of Study: A Multi-Center,
More informationIndividual Study Table Referring to Part of Dossier: Use Only) Name of Study Drug:
2.0 Synopsis AbbVie Inc. Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Adalimumab (Humira ) Page: Name of Active Ingredient: Adalimumab
More informationProduct: Darbepoetin alfa Clinical Study Report: Date: 22 August 2007 Page 2 of 14145
Date: 22 ugust 2007 Page 2 of 14145 2. SYNOPSIS Name of Sponsor: mgen Inc., Thousand Oaks, C, US Name of Finished Product: ranesp Name of ctive Ingredient: Darbepoetin alfa Title of Study: Randomized,
More informationInvestigators, study sites Multicenter, 35 US sites. Coordinating Investigator: Richard Bergenstal, MD
STUDY SYNOPSIS Study number Title HMR1964A/3502 Apidra (insulin glulisine) administered in a fixed-bolus regimen vs. variable-bolus regimen based on carbohydrate counting in adult subjects with type 2
More informationHydrocodone/Acetaminophen Extended-Release Tablets M Clinical Study Report R&D/09/1109
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: ABT-712 Volume: Hydrocodone/Acetaminophen Extended-Release Name
More informationSynopsis Style Clinical Study Report SAR ACT sarilumab Version number : 1 (electronic 1.0)
SYNOPSIS Title of the study: A randomized, double-blind, parallel-group, placebo- and active calibrator-controlled study assessing the clinical benefit of SAR153191 subcutaneous (SC) on top of methotrexate
More informationAMR101, a Pure-EPA Omega-3 Fatty Acid, Lowers Triglycerides in Patients with Very High Triglycerides Without Raising LDL- C: The MARINE Study
AMR101, a Pure-EPA Omega-3 Fatty Acid, Lowers Triglycerides in Patients with Very High Triglycerides Without Raising LDL- C: The MARINE Study HE Bays, 1 CM Ballantyne, 2 JJ Kastelein, 3 E Stein, 4 JL Isaacsohn,
More informationPaliperidone: Clinical Protocol R076477SCH4012, CR Amendment INT-1
Paliperidone: Clinical Protocol R076477SCH4012, CR013771 Amendment INT-1 A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of a Fixed
More informationSponsor Novartis. Generic Drug Name Fluvastatin. Therapeutic Area of Trial Dyslipidemia
Page 1 Sponsor Novartis Generic Drug Name Fluvastatin Therapeutic Area of Trial Dyslipidemia Approved Indication Therapeutic area and approved indications in Germany: Hypercholesterolemia (HC), combined
More informationABT-493/ABT-530 M Clinical Study Report Post-Treatment Week 12 Primary Data R&D/16/0162. Referring to Part of Dossier: Volume: Page:
2.0 Synopsis AbbVie Inc. Name of Study Drug: ABT-493/ABT-530 Name of Active Ingredient: ABT-493: (3aR,7S,10S,12R,21E,24aR)- 7-tert-butyl-N-{(1R,2R)-2- (difluoromethyl)-1-[(1- methylcyclopropane-1- sulfonyl)carbamoyl]cyclopropyl}-20,20-
More informationCHAPTER IV RESEARCH METHOD. This study belongs to the field of Internal Medicine, specifically the field
CHAPTER IV RESEARCH METHOD 4.1 Research fields This study belongs to the field of Internal Medicine, specifically the field of Infectious and Tropical Disease. 4.2 Research location and period This study
More informationPrincipal Investigator: Robert J. Jones, MD, Beatson Cancer Center, 1053 Great Western Road, Glasgow; United Kingdom
SYNOPSIS Issue Date: 14 October 2010 Document No.: EDMS-ERI-13494974:2.0 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Protocol No.: COU-AA-BE Cougar Biotechnology, Inc.
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationReferring to Part of Dossier: Volume: Page:
Synopsis Abbott Laboratories Name of Study Drug: Adalimumab Name of Active Ingredient: Adalimumab Title of Study: Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority
More informationSYNOPSIS. Issue Date: 31 July 2013
SYNOPSIS Issue Date: 31 July 2013 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Janssen Research & Development, LLC YONDELIS Trabectedin (R279741) Protocol No.: ET743-OVC-1003
More informationSYNOPSIS. Issue Date: 25 Oct 2011
SYNOPSIS Issue Date: 25 Oct 2011 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Janssen Research & Development STELARA Ustekinumab Protocol No.: Title of Study: Study Name:
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationAntisense Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes
Antisense Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes Andres Digenio, MD, PhD; Richard L. Dunbar, MD; Veronica J. Alexander,
More informationIndividual Study Table Referring to Part of Dossier: Volume: Page:
2.0 Synopsis Abbott Laboratories Name of Study Drug: ABT-639 Name of Active Ingredient: ABT-639 Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Title
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationTitle of Study: Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil
SYNOPSIS Name of Sponsor/Company Name of Finished Product REMINYL Name of Active Ingredient(s) Galantamine hydrobromide Issue Date: 18 October 2013 Protocol No.: Title of Study: Evaluation of Efficacy
More informationAdalimumab M Clinical Study Report Final R&D/16/0603
Methodology (Continued): The 70-day safety follow-up period started from the last dose of study drug, but was not required for any subject who initiated commercial Humira after study completion. Additional
More informationPFIZER INC. These results are supplied for informational purpose only. Prescribing decisions should be made based on the approved package insert.
Public Disclosure Synopsis Protocol A3924 4 November 24 Final PFIZER INC. These results are supplied for informational purpose only. Prescribing decisions should be made based on the approved package insert.
More informationSynopsis. Clinical Report Synopsis for Protocol Name of Company: Otsuka Pharmaceutical Development & Commercialization, Inc.
Synopsis Clinical Report Synopsis for Protocol 197-02-220 Name of Company: Otsuka Pharmaceutical Development & Commercialization, Inc. Name of Product: Tetomilast (OPC-6535) Study Title: A Phase 3, Multicenter,
More information24-Week CNTO1275PSA3001 Clinical Study Report
24-Week CNTO1275PSA3001 Clinical Study Report SYNOPSIS Issue Date: 17 Jan 2013 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Janssen Research & Development, Inc Ustekinumab
More informationBristol-Myers Squibb
A Study of the Safety and Efficacy of plus Tenofovir in Adults with Chronic Hepatitis B Virus Infection with Previous Nucleoside/Nucleotide Treatment Failure () FINAL CLINICAL STUDY REPORT EUDRACT Number:
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Gaudet D, Alexander VJ, Baker BF, et al. Antisense inhibition
More informationBRL /RSD-101C0F/1/CPMS-716. Report Synopsis
Report Synopsis Study Title: A Multicenter, Open-label, Six-Month Extension Study to Assess the Long-Term Safety of Paroxetine in Children and Adolescents with Major Depressive Disorder (MDD) or Obsessive-Compulsive
More informationSYNOPSIS. Administration: subcutaneous injection Batch number(s):
SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, 2-arm parallel-group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0010 on top
More information2.0 Synopsis. ABT-358 M Clinical Study Report R&D/06/099. (For National Authority Use Only) to Item of the Submission: Volume:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Zemplar Injection Name of Active Ingredient: Paricalcitol Individual Study Table Referring to Item of the Submission: Volume: Page: (For National Authority
More informationThese results are supplied for informational purposes only.
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov
More informationJanssen-Cilag EMEA Medical Affairs a division of Janssen Pharmaceuticals N.V.
SYNOPSIS Issue Date: Final 22 July 2009 [Document No.: EDMS-PSDB-9245102] Name of Sponsor/Company Name of Finished Product Risperdal Consta Name of Active Ingredient(s) Protocol No.: RIS-BMN-3001 Janssen-Cilag
More informationJuxtapid. Juxtapid (lomitapide) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Juxtapid Page: 1 of 6 Last Review Date: September 20, 2018 Juxtapid Description Juxtapid (lomitapide)
More informationReferring to Part of Dossier: Volume: Page:
Synopsis AbbVie Inc. Name of Study Drug: ABT-450, ritonavir, ABT-333, ribavirin Name of Active Ingredient: ABT-450: (2R,6S,12Z,13aS,14aR,16aS)-N- (cyclopropylsulfonyl)-6-{[(5- methylpyrazin-2-yl)carbonyl]amino}-
More informationSITA 100 mg (n = 378)
Supplementary Table 1. Summary of Sulfonylurea Background Therapy at Baseline and During the Treatment Period. Sulfonylurea at baseline, n (%) SITA 100 mg (n = 378) CANA 300 mg (n = 377) Total (N = 755)
More information2.0 Synopsis. Adalimumab M Clinical Study Report R&D/04/900. (For National Authority Use Only) Referring to Part of Dossier: Volume:
2. Synopsis Abbott Laboratories Name of Study Drug: Name of Active Ingredient: Title of Study: Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Phase
More informationSponsor / Company: Sanofi Drug substance(s): HOE901-U300 (insulin glargine) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationJohnson & Johnson Pharmaceutical Research & Development, L.L.C.
SYNOPSIS Issue Date: 27 April 2009 Document No.: EDMS-PSDB-9908562:2.0 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient Johnson & Johnson Pharmaceutical Research & Development,
More information2.0 Synopsis. Adalimumab M Clinical Study Report Final R&D/15/1093. (For National Authority Use Only)
2.0 Synopsis AbbVie Inc. Name of Study Drug: Adalimumab Name of Active Ingredient: Adalimumab Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Title
More information